| Literature DB >> 33150141 |
Pocharapong Jenjitranant1, Pasu Tansakul1, Pokket Sirisreetreerux1, Charoen Leenanupunth1, Sopon Jirasiritham2.
Abstract
PURPOSE: Kidney transplantation is one of the best treatment options for end-stage renal disease with an incidence of urologic complications of 2.5 to 30%. One of the most serious and frequent urological complications is urinary leakage from ureteroneocystostomy anastomosis. The purpose of this study was to evaluate risk factors of urinary leakage from ureteroneocystostomy anastomosis after kidney transplantation. PATIENTS AND METHODS: A retrospective study was performed on patients who received kidney transplantation and were diagnosed with urinary leakage thereafter based on renal scan or drain creatinine per serum creatinine compared with patients in control group. Risk factor assessment was based on inpatient and outpatient information from hospital database.Entities:
Keywords: anastomotic leak; kidney transplantation; postoperative complications; risk factors
Year: 2020 PMID: 33150141 PMCID: PMC7604254 DOI: 10.2147/RRU.S272899
Source DB: PubMed Journal: Res Rep Urol ISSN: 2253-2447
Patients’ Baseline Characteristics
| Characteristics | Total | Non-Leakage | Leakage | |
|---|---|---|---|---|
| (n=459) | (n=439) | (n=20) | ||
| Sex, n(%) | ||||
| Male | 274(59.69) | 261(59.45) | 13(65.00) | 0.621 |
| Female | 185(40.31) | 178(40.55) | 7(35.00) | |
| Age (years), mean±standard deviation | 42.83±12.74 | 42.95±12.77 | 40.10±12.04 | 0.327 |
| Body mass index (kg/m2), mean±standard deviation | 22.35±4.19 | 22.34±4.24 | 22.48±3.06 | 0.880 |
| Underlying comorbidity, n(%), | ||||
| Diabetes mellitus | 82(17.86) | 79(18.00) | 3(15.00) | 0.732 |
| Hypertension | 406(88.45) | 388(88.38) | 18(90.00) | 0.825 |
| Dyslipidemia | 75(16.34) | 74(16.86) | 1(5.00) | 0.222 |
| Chronic obstructive pulmonary disease | 1(0.22) | 1(0.23) | 0 | 0.999 |
| Ischemic heart disease | 5(1.09) | 5(1.14) | 0 | |
| Cause of end-stage renal disease, n(%), n=367 | ||||
| Diabetes mellitus | 16(4.36) | 16(4.61) | 0 | 0.999 |
| Immunoglobulin A nephropathy | 28(7.63) | 26(7.49) | 2(10.00) | 0.658 |
| Obstructive uropathy | 3(0.82) | 2(0.58) | 1(5.00) | 0.155 |
| Hypertension | 15(4.09) | 14(4.03) | 1(5.00) | 0.576 |
| Polycystic kidney disease | 8(2.18) | 7(2.02) | 1(5.00) | 0.364 |
| Unknown cause | 219(59.67) | 207(59.65) | 12(60.00) | 0.976 |
| Autosomal-dominant polycystic kidney disease | 3(0.65) | 3(0.68) | 0 | |
| Antineutrophil cytoplasmic autoantibody vasculitis | 1(0.22) | 1(0.23) | 0 | |
| Renal calculi/stone | 6(1.31) | 6(1.37) | 0 | |
| Chronic tubulointerstitial nephropathy | 1(0.22) | (0.23) | 0 | |
| Diabetic kidney disease | 14(3.05) | 14(3.19) | 0 | |
| Focal segmental glomerulosclerosis | 12(2.61) | 11(2.51) | 1(5.00) | |
| Glomerulonephritis | 18(3.92) | 17(3.87) | 1(5.00) | |
| Systemic lupus erythematous | 17(3.70) | 16(3.64) | 1(5.00) | |
| Membranous nephropathy | 2(0.44) | 2(0.46) | 0 | |
| Nephrotic syndrome | 1(0.22) | 1(0.23) | 0 | |
| Non-steroidal anti-inflammatory-related | 2(0.44) | 2(0.46) | 0 | |
| Posterior urethral valves | 1(0.22) | 1(0.23) | 0 | |
| Renal hypoplasia | 1(0.22) | 1(0.23) | 0 | |
| Wegener’s disease | 1(0.22) | 1(0.23) | 0 | |
| Renal replacement therapy, n(%), n=433 | ||||
| Continuous ambulatory peritoneal dialysis | 75(16.34) | 71(16.17) | 4(20.00) | 0.651 |
| Hemodialysis | 358(78.00) | 342(77.90) | 16(80.00) | 0.825 |
| once per week | 1(0.22) | 1(0.23) | 0 | |
| twice per week | 120(26.14) | 115(26.20) | 5(25.00) | |
| three times per week | 237(51.63) | 226(51.48) | 11(55.00) | |
| Urine output each day, n(%), n=452 | ||||
| No | 290(64.16) | 284(64.84) | 6(42.86) | 0.091 |
| Yes | 162(35.84) | 154(35.16) | 5(57.14) | |
| Urine (mL/day), median(range) | 200(10–1500) | 200(10–1500) | 100(20–500) | 0.108 |
Comparison of Patients’ Perioperative Factors Between the Non-Leakage and Leakage Groups
| Characteristics | Total | Non-Leakage | Leakage | |
|---|---|---|---|---|
| (n=459) | (n=439) | (n=20) | ||
| Donor, n(%) | ||||
| Living donor | 200(43.57) | 194(44.19) | 6(30.00) | 0.283 |
| Open | 72(36.00) | 70(36.08) | 2(33.33) | 0.890 |
| Laparoscopic | 128(64.00) | 124(63.92) | 4(66.67) | |
| Deceased donor, standard criteria | 246(53.59) | 232(52.85) | 14(70.00) | |
| Deceased donor, expanded criteria | 13(2.83) | 13(2.96) | 0 | |
| Kidney graft, median(range) | ||||
| Cold ischemic time (min) | 800(1–2025) | 789(1–2025) | 1103(11–1812) | 0.024* |
| Warm ischemic time (min) | 30(1–115) | 30(1–115) | 32.5(2–64) | 0.897 |
| Operative time (min) | 275(120–1165) | 275(120–1165) | 270(195–345) | 0.717 |
| Ureteral reimplantation technique, n(%), n=425 | ||||
| Continuous Lich–Grégoire | 5(1.18) | 4(0.99) | 1(5.26) | 0.205 |
| Interrupted Lich–Grégoire | 420(98.82) | 402(99.01) | 18(94.74) | |
| Suture material: Anastomosis, n(%), n=436 | ||||
| PDS 6–0 | 1(0.23) | 1(0.24) | 0 | 0.000 |
| Maxon 6–0 | 9(2.06) | 6(1.44) | 3(15.00) | |
| Maxon 5–0 | 424(97.25) | 408(98.06) | 16(80.00) | |
| Maxon 4–0 | 1(0.23) | 1(0.24) | 0 | |
| Maxon 6–0 + Maxon 5–0 | 1(0.23) | 0 | 1(5.00) | |
| Suture material: Tunnel, n(%), n=449 | ||||
| Vicryl 2–0 | 10(2.23) | 9(2.09) | 1(5.26) | 0.403 |
| Vicryl 3–0 | 357(79.51) | 340(79.07) | 17(89.47) | |
| Vicryl 4–0 | 6(1.34) | 6(1.40) | 0 | |
| Chromic gut 3–0 | 76(16.93) | 75(17.44) | 1(5.26) | |
| Chromic gut 4–0 | 0 | 0 | 0 | |
| Bladder capacity (mL), median(range) n=417 | 200(50–500) | 200(50–500) | 200(50–300) | 0.743 |
| Time to removing the Foley catheter (days), median(range) | 5(0–75) | 5(0–75) | 5.5(5–45) | 0.080 |
| Time to removing the double-J stent (days), median(range) | 15(3–79) | 15(3–79) | 15.5(7–73) | 0.114 |
Clinical Presentation, Treatment, and Outcomes of Urinary Leakage
| Factors | Leakage |
|---|---|
| (n=20) | |
| Time to urine leakage (days), median(interquartile range) | 16 (7-396) |
| Clinical presentation, no. of patients | |
| Urinary tract infection | 2 |
| Perinephric fluid collection confirmed using ultrasound | 2 |
| Fluid leakage from the wound | 2 |
| Massive fluid volume from the drain | 8 |
| Other | 3 |
| Treatment, no. of patients | |
| Retained Foley catheter | 6 |
| Surgery | 14 |
| Surgical treatment, no. of patients | |
| Open ureteroneocystostomy | 8 |
| Open ureteroureterostomy with native ureter | 4 |
| Nephrectomy | 2 |
| Outcome after surgical treatment, no. of patients | |
| No leakage | 8 |
| Nephrectomy of the transplanted kidney | 3 |
| Continued leakage | 2 |
| Death | 1 |
| Time to Death (days), N=1 | 59 |
Univariate and Multivariate Analyses for the Risk Factors for Urinary Leakage Complications
| Data | Univariate | p-value | Multivariate | p-value |
|---|---|---|---|---|
| OR(95% CI) | OR(95% CI) | |||
| Gender | ||||
| Male | 1 | |||
| Female | 0.789(0.31–2.02) | 0.622 | ||
| Age(years) | 0.982(0.95–1.02) | 0.328 | ||
| BMI(kg/m2) | 1.008(0.91–1.12) | 0.880 | ||
| Donor | ||||
| Living donor | 1 | |||
| Deceased donor | 1.847(0.69–4.87) | 0.217 | ||
| Kidney graft | ||||
| Cold ischemic time(mins) | 1.092(1.00–1.18) | 0.040 | 1.049(0.95–1.15) | 0.305 |
| Warm ischemic time(mins) | 0.990(0.98–1.02) | 0.993 | ||
| Operative time(mins) | 0.996(0.98–1.01) | 0.484 | ||
| Technique Reimplant ureter | ||||
| Continuous Lich-Grégoire | 1 | |||
| Interrupt Lich-Grégoire | 0.179(0.02–1.68) | 0.133 | ||
| Suture material size used for anastomosis | ||||
| Size ≤ 5–0 | 1 | 1 | ||
| Size 6–0 | 14.607(3.87–55.02) | 0.000 | 12.294(2.75–54.90) | 0.001 |
| Bladder capacity(mL), | 0.997(0.98–1.01) | 0.571 | ||
| Duration of Foley catheter(day) | 1.046(0.99–1.09) | 0.057 | 1.033(0.97–1.09) | 0.278 |
| Duration of DJ stent insertion(day) | 1.071(1.02–1.12) | 0.001 | 1.071(1.02–1.11) | 0.002 |
Univariate and Multivariate Analyses for the Risk Factors of Overall Urological Complications
| Risk Factor for Complications | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Sex, n(%) | ||||
| Male | 1 | 1 | ||
| Female | 2.890(1.96–4.25) | 0.000 | 3.592(2.35–5.48) | <0.001 |
| Age (years), mean±standard deviation, | 1.013(0.99–1.02) | 0.066 | 1.007(0.99–1.02) | 0.349 |
| Body mass index (kg/m2), mean±standard deviation, | 1.043(0.99–1.09) | 0.060 | 1.073(1.02–1.13) | 0.006 |
| Underlying comorbidity, | ||||
| Diabetes mellitus | 1.128(0.69–1.82) | 0.621 | ||
| Hypertension | 0.835(0.47–1.48) | 0.538 | ||
| Dyslipoproteinemia | 0.888(0.53–1.46) | 0.644 | ||
| Ischemic heart disease | 0.301(0.03–2.71) | 0.285 | ||
| Other | ||||
| Renal replacement therapy, n=433 | ||||
| Continuous ambulatory peritoneal dialysis | 0.888(0.53–1.46) | 0.644 | ||
| Hemodialysis | 1.405(0.89–2.21) | 0.139 | ||
| Urine output each day, n(%), n=452 | ||||
| No | 1 | |||
| Yes | 0.900(0.61–1.32) | 0.596 | ||
| Urine volume (mL/day), median(range) | 0.963(0.86–1.06) | 0.474 | ||
| Donor, n=455 | ||||
| Living donor | 1 | 1 | ||
| Deceased donor, standard criteria | 1.438(0.98–2.10) | 0.060 | 0.451(0.14–1.39) | 0.167 |
| Deceased donor, expanded criteria | 1.044(0.32–3.41) | 0.942 | 0.097(0.04–1.28) | 0.097 |
| Kidney graft, median(range), | ||||
| Cold ischemic time (min) | 1.036(1.00–1.07) | 0.033 | 1.085(0.98–1.19) | 0.092 |
| Warm ischemic time (min) | 0.887(0.36–2.13) | 0.789 | ||
| Operative time (min) | 0.977(0.74–1.27) | 0.866 | ||
| Ureteral reimplantation technique, n=425 | ||||
| Continuous Lich–Grégoire | 1 | |||
| Interrupted Lich–Grégoire | 1.263(0.21–7.63) | 0.799 | ||
| Suture material: Tunnel, n=449 | ||||
| Vicryl 2–0 | 1 | |||
| Vicryl 3–0 | 3.140(0.65–14.99) | 0.151 | ||
| Vicryl 4–0 | 3.999(0.43–37.10) | 0.223 | ||
| Chromic gut 3–0 | 4.685(0.93–23.53) | 0.061 |
Abbreviations: OR, odds ratio; CI, confidence interval.